Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Debasish F. Roychowdhury"'
Autor:
Robert Paine, Robert Chasse, E Scott Halstead, Jay Nfonoyim, David J Park, Timothy Byun, Bela Patel, Guido Molina-Pallete, Estelle S Harris, Fiona Garner, Lorinda Simms, Sanjeev Ahuja, John L McManus, Debasish F Roychowdhury
Publikováno v:
Military medicine.
Introduction Granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein produced in the lung, is essential for pulmonary host defense and alveolar integrity. Prior studies suggest potential benefits in several pulmonary conditions, includin
Autor:
Simon Authier, Colleen Mockbee, Mylene Pouliot, Debasish F Roychowdhury, Anne-Marie Downey, Wieslaw Wierzbicki, Yifei Zhong
Publikováno v:
International Journal of Radiation Biology. 97:S100-S116
High dose ionizing radiation exposure is associated with myelo-depression leading to pancytopenia and the expected clinical manifestations of acute radiation syndrome (ARS). Herein, we evaluated the efficacy of sargramostim (LeukineA randomized and b
Publikováno v:
Cureus
Drug development in oncology today routinely focuses on approaches that utilize the patients’ immune system to destroy the malignancy. Combinatorial approaches of antineoplastic agents, both new and old, are being incorporated in the armamentarium
Autor:
Gary A. Ulaner, Jeffrey H. Hager, Umar Mahmood, Aditya Bardia, Carlos L. Arteaga, José Baselga, Eric P. Winer, Peter J. Rix, Maura N. Dickler, H. Charles Manning, Edna Chow Maneval, Debasish F. Roychowdhury, Ingrid A. Mayer
Publikováno v:
Cancer Research. 75:P1-13
Background: Evidence that ER can signal in both ligand-dependent and independent manner in endocrine resistant breast cancer (BC) provides rationale for therapies that are not only functional antagonists of ER but also reduce ER levels, thus targetin
Autor:
Eunsik Lee, Pamela Salman, Lauren McCann, Cora N. Sternberg, Cezary Szczylik, Robert E. Hawkins, Oleg Gladkov, Lini Pandite, Ian D. Davis, John Wagstaff, Mei Chen, Debasish F. Roychowdhury, Jozef Mardiak, Alexander Kavina, Carlos H. Barrios, J. J. Zarba
Publikováno v:
Journal of Clinical Oncology. 28:1061-1068
Purpose Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and sa
Autor:
Debasish F. Roychowdhury, Henri Roché, Hans-Joachim Stemmler, Cristina Oliva, Joanne L. Blum, Paolo Paoletti, Minetta C. Liu, Richard Greil, Devchand Paul, Dominique Lossignol, Denise A. Yardley, Denise Zembryki, Eric P. Winer, Sibylle Loibl, Nan Lin, Christos Christodoulou, Stephen D. Rubin, Eva Ciruelos, Bernie Dharan, Stefania Gori, Andrew M Wardley, Klaudia Steplewski, Adam Brufsky, Véronique Diéras
Publikováno v:
Clinical Cancer Research. 15:1452-1459
Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical ch
Autor:
Stephen D. Rubin, Patrice Viens, Cristina Oliva, Debasish F. Roychowdhury, Arlene Chan, B. Newstat, John Crown, Bella Kaufman, S. Stein, Mario Campone, Dimosthenis Skarlos, Michael F. Press, Charles E. Geyer, Deborah Lindquist, C. Gilles Romieu, Paolo Paoletti, Agnieszka Jagiełło-Gruszfeld, Neville Davidson, Tadeusz Pienkowski, Veira Gorbounova, Michelle Casey, Stephen Chan, Johannes Isaac Raats, David Cameron
Publikováno v:
Breast Cancer Research and Treatment. 112:533-543
Purpose Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitab
Publikováno v:
Cancer. 77:1419-1426
BACKGROUND This study was conducted to determine the prognostic significance of tumor angiogenesis, c-erbB2, epidermal growth factor receptor, Ki-67, and p53 for patients with nasopharyngeal carcinoma. METHODS In this retrospective study, the authors
Autor:
James B. Bussel, Debasish F. Roychowdhury, Michael Arning, Bhabita Mayer, Abdulgabar Salama, Gregory Cheng, Tahir Shamsi, Bethan Psaila, Julian Jenkins, Nicole L. Stone, Drew Provan, Lidia Kovaleva
Publikováno v:
Lancet (London, England). 373(9664)
Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombopoiesis, leading to increased platelet production. This study assessed the efficacy, safety, and tolerability of once daily eltrombopag 50 mg, and explored th
Autor:
T. Z. Zaks, E. A. Perez, Cristina Oliva, R. Rafi, Debasish F. Roychowdhury, S. Stein, Mark S. Berger, Julie Byrne, Anne-Marie Martin, I. W. Hammond
Publikováno v:
Journal of Clinical Oncology. 24:583-583
583 Background: Lapatinib is an orally bioavailable reversible, dual tyrosine kinase ErbB1 and ErbB2 inhibitor. Trastuzumab, an ErbB2 inhibitor, has been associated with cardiotoxicity. Methods: Left ventricular ejection fraction (LVEF) was monitored